Ascletis Pharma Inc. (1672.HK)
HKD 6.55
(3.15%)
HKD 6.55
(3.15%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.13 CNY | 61.76% |
| 2022 | -0.34 CNY | -88.89% |
| 2021 | -0.18 CNY | 28.0% |
| 2020 | -0.25 CNY | -66.67% |
| 2019 | -0.15 CNY | -1685.71% |
| 2018 | -0.01 CNY | 82.54% |
| 2017 | -0.05 CNY | -101.26% |
| 2016 | -0.02 CNY | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.06 CNY | -6.13% |
| 2024 Q2 | -0.06 CNY | 0.0% |
| 2023 Q1 | -0.01 CNY | 92.4% |
| 2023 FY | - CNY | 61.76% |
| 2023 Q4 | -0.06 CNY | 0.0% |
| 2023 Q3 | -0.06 CNY | -694.74% |
| 2023 Q2 | -0.01 CNY | 0.0% |
| 2022 FY | - CNY | -88.89% |
| 2022 Q4 | -0.10 CNY | 0.0% |
| 2022 Q3 | -0.10 CNY | -146.91% |
| 2022 Q2 | -0.04 CNY | 0.0% |
| 2022 Q1 | -0.04 CNY | -0.75% |
| 2021 Q3 | -0.04 CNY | 20.4% |
| 2021 Q2 | -0.05 CNY | 0.0% |
| 2021 FY | - CNY | 28.0% |
| 2021 Q4 | -0.04 CNY | 0.0% |
| 2021 Q1 | -0.05 CNY | 33.55% |
| 2020 Q4 | -0.08 CNY | 0.0% |
| 2020 Q3 | -0.08 CNY | -207.69% |
| 2020 Q2 | -0.02 CNY | 0.0% |
| 2020 Q1 | -0.02 CNY | -6.47% |
| 2020 FY | - CNY | -66.67% |
| 2019 Q3 | -0.02 CNY | -3.57% |
| 2019 FY | - CNY | -1685.71% |
| 2019 Q4 | -0.02 CNY | 0.0% |
| 2019 Q1 | -0.02 CNY | 1.75% |
| 2019 Q2 | -0.02 CNY | 0.0% |
| 2018 Q2 | 0.03 CNY | 4100.0% |
| 2018 Q3 | -0.02 CNY | -171.25% |
| 2018 Q4 | -0.02 CNY | 0.0% |
| 2018 FY | - CNY | 82.54% |
| 2018 Q1 | -0.00 CNY | 98.38% |
| 2017 Q1 | -0.00 CNY | 0.0% |
| 2017 FY | - CNY | -101.26% |
| 2017 Q2 | -0.02 CNY | -746.15% |
| 2017 Q4 | -0.05 CNY | 0.0% |
| 2017 Q3 | -0.05 CNY | -125.0% |
| 2016 FY | - CNY | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 0.01 HKD | 1271.171% |
| CK Life Sciences Int'l., (Holdings) Inc. | 0.00 HKD | 7322.222% |